Ipilimumab, an antibody targeting CTLA-4, appears to restore tumor immunity at the priming phase and prolongs overall survival in some patients, whereas anti-PD-1/PD-L1 antibodies restore immune function in the tumor microenvironment7,8. This evidence concerns the gene PDCD1 and neoplasm.